KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.J Am Acad Child Adolesc PsychiatryPMID 35577034无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.Emerg Microbes InfectPMID 35686572PMC93474732022-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).Br J DermatolPMID 35791755PMC100870452022-Dec0.98未发现恶性肿瘤人群证据。待处理
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.Emerg Microbes InfectPMID 35792746PMC93312252022-Dec0.98未发现恶性肿瘤人群证据。待处理
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.Hematol OncolPMID 35858181无 PMCID2022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.J Diabetes InvestigPMID 35861630PMC97202262022-Dec0.98未发现恶性肿瘤人群证据。待处理
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.Am J Obstet GynecolPMID 35863457无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.Ann Allergy Asthma ImmunolPMID 35973655无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Effectiveness of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of the Needle Tip in Decreasing Infectious Complications After Transrectal Prostate Biopsy: A Randomized Controlled Trial.J UrolPMID 36006040无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.Br J HaematolPMID 36017875PMC98051702022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.Lancet Infect DisPMID 36037823无 PMCID2022-Dec0.85The study is a randomized Phase III trial of a drug-containing vaccine intervention (HPV 16/18 vaccine) reporting final efficacy results for human cancer prevention. However, the primary efficacy endpoints (high-grade genital lesions, persistent infection) are categorical outcomes (vaccine efficacy percentages), not the required time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR).待处理
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.Clin Lung CancerPMID 36038416无 PMCID2022-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).Cancer SciPMID 36062851PMC97460482022-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.Lancet Infect DisPMID 36075233PMC94442372022-Dec0.98未发现恶性肿瘤人群证据。待处理
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.Br J DermatolPMID 36082590PMC100919962022-Dec0.98未发现恶性肿瘤人群证据。待处理
Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).PituitaryPMID 36085339PMC96756602022-Dec0.98未发现恶性肿瘤人群证据。待处理
A Phase III, Randomized, Controlled Trial Comparing Open Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.Ann Surg OncolPMID 36085388PMC106736822022-Dec0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Respir MedPMID 36087611PMC94514992022-Dec0.98未发现恶性肿瘤人群证据。待处理
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.Ann Rheum DisPMID 36109142PMC96641112022-Dec0.90The study is a Phase III randomized controlled trial in rheumatoid arthritis, not oncology. The primary and key secondary endpoints are ACR20 response and DAS28(CRP)<3.2, which are clinical response/proportion-based outcomes, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).待处理
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Infect DisPMID 36113538PMC96397962022-Dec0.98未发现恶性肿瘤人群证据。待处理
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.Hypertens ResPMID 36123398无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.Clin Transl SciPMID 36126241PMC97471242022-Dec0.98未发现恶性肿瘤人群证据。待处理
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.J Thromb HaemostPMID 36138517PMC98279312022-Dec0.98未发现恶性肿瘤人群证据。待处理
Perspectives on rosacea patient characteristics and quality of life using baseline data from a phase 3 clinical study conducted in Japan.J DermatolPMID 36177741PMC100922952022-Dec0.98未发现恶性肿瘤人群证据。待处理
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.Lancet Gastroenterol HepatolPMID 36183738无 PMCID2022-Dec0.95The record describes a randomized, Phase 3 trial of drug interventions (TETA4 vs. penicillamine) for Wilson disease, which is not a human malignant neoplasm. The primary efficacy endpoint is serum non-caeruloplasmin-bound copper (NCC), a continuous biomarker, not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.待处理
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.BreastPMID 36223695PMC95632102022-Dec0.95This is a randomized Phase III trial of trastuzumab in early breast cancer, but the study's primary endpoints are pharmacokinetics, patient preference, and safety. It does not report a time-to-event efficacy endpoint like overall survival or disease-free survival.待处理
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.Ann OncolPMID 36228963PMC102078562022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.Gynecol OncolPMID 36244828无 PMCID2022-Dec0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial.Radiother OncolPMID 36265685无 PMCID2022-Dec0.80The study meets oncology, human, randomized, and Phase III criteria, but it does not meet the required drug intervention or time-to-event efficacy endpoint criteria. The intervention is a non-drug radiotherapy technique, and the primary reported outcome is a toxicity measure (breast induration), not a time-to-event efficacy endpoint.待处理
Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.Cancer Chemother PharmacolPMID 36305957PMC96370742022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.Arterioscler Thromb Vasc BiolPMID 36325897PMC97501072022-Dec0.98未发现恶性肿瘤人群证据。待处理
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.Eur J CancerPMID 36327527PMC97504972022-Dec0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).Cancer Commun (Lond)PMID 36336841PMC97597622022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.Lancet Diabetes EndocrinolPMID 36356613PMC98474802022-Dec0.98未发现恶性肿瘤人群证据。待处理
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.Nat MicrobiolPMID 36357712PMC101661872022-Dec0.98未发现恶性肿瘤人群证据。待处理
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.Eur J CancerPMID 36368252无 PMCID2022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.EBioMedicinePMID 36370634PMC96644022022-Dec0.98未发现恶性肿瘤人群证据。待处理
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.Lancet OncolPMID 36370716无 PMCID2022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.Psychiatry ResPMID 36375329无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients.CNS DrugsPMID 36385453无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.Lancet NeurolPMID 36402160无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.Lung CancerPMID 36410210无 PMCID2022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Multiple sclerosis clinical decision support system based on projection to reference datasets.Ann Clin Transl NeurolPMID 36412095PMC97353732022-Dec0.98未发现恶性肿瘤人群证据。待处理
Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts.Am J TransplantPMID 36453709无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.ESMO OpenPMID 36455504PMC98084432022-Dec0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix® 30 in Type 2 diabetes patients.J Comp Eff ResPMID 36511777无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study.J DiabetesPMID 36515221PMC97893912022-Dec0.98未发现恶性肿瘤人群证据。待处理
[Advanced Medical Care].Gan To Kagaku RyohoPMID 36539239无 PMCID2022-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
MPFF 1000 mg chewable once daily vs. MPFF 500 mg twice daily in chronic venous disease: the double-blind, randomized, non-inferiority CHEWY trial.Int AngiolPMID 36598370无 PMCID2022-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.Future OncolPMID 36753353无 PMCID2022-Dec0.80The record describes a subgroup analysis of a Phase III randomized trial (ARAMIS) with drug intervention and time-to-event endpoints, but it is not the original primary result report of the trial. It is a secondary analysis focusing on a specific patient population, thus excluded per criteria.待处理